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A B S T R A C T 
Aromatase or CYP19 is the rate limiting enzyme in converting androgen to estrogen. 
Estrogen is important in the prevention of the cardiovascular disease. Previous 
researches have shown that genistein, a dietary phytoestrogen, could increase LDL 
receptor and apolipoprotein A-1 expression, but the mechanism is unclear. This study 
investigated the relationship between genistein and estrogen synthesis in a human 
hepatic cell line. On the other hand, the female hormone is critical in the initiation 
and development of breast cancer. Environmental toxicants are thought to play a role 
in several estrogen-dependent diseases including breast cancer. Therefore, the other 
objective of this study was to determine the effect of TCDD on aromatase expression 
and activity in human breast cancer cell lines in culture. 
In this study, 0.1 )iM to lOjiM genistein could induce aromatase activity in a dose 
dependent manner in ERa-transfected HepG2 cells. The induction of aromatase 
activity was consistent with the up-regulations in aromatase protein expression, 
mRNA expression and promoter LI activity. From the promoter deletion analysis, 
we found that the sequences between -212 to -190 and -300 to -260 bp upstream of 
exon I.l might be responsible for the activity induced by genistein. Within these 
regions of promoter 1.1，several AP-1 sites can be located. Genistein also increased 
the AP-1 transactivation activity, suggesting that AP-1 might be involved in the 
induced aromatase activity in ERa-transfected HepG2 cells. Besides, inhibition of 
p38 pathway could partly abolish the genistein-induced aromatase activity. The 
possibility that genistein promotes the aromatase activity through p38 kinase 
activation and ER phosphorylation needs further investigation. 
Tritiated water release assay had shown that TCDD could increase aromatase activity 
in MCF-7, but not the other breast cancer cells. IrjM to lOrjM TCDD were found to 
increase the aromatase activity in MCF-7 cells, but not in human CYP19 
Supersomes®. These results indicated that the enzyme induction was not the result of 
a direct stimulation on the aromatase enzyme complex. TCDD could up-regulate the 
aromatase protein and mRNA expression in MCF-7 cells. However, it could not 
induce promoter 1.1，I.3/II activity and AP-1 transactivation activity. We also 
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investigated the role of ER, MAP kinase and protein kinase pathways by adding the 
corresponding inhibitors. The results showed that ER, ERK, JNK, PKA and PKC 
might be involved in the regulation process. 
Instead of regulation through typical transcriptional control, data in the present study 
suggested that TCDD could increase the half-life of CYP19 mRNA. Such induction 
can be abolished by ERK inhibitor. However, the mechanism through which TCDD 
mediated aromatase mRNA degradation was not fully understood. The aromatase 
activity, protein and mRNA expression in MCF-7 cells expressing ERK were higher 
than that of the control cells. On the other hand, TCDD could increase the active 
ERK protein in MCF-7 in a dose-dependent manner, and ERK inhibitor could block 
TCDD-induced aromatase. Combining these observations, the aromatase activity 
could be mediated by ERK. 
In the present study, we demonstrated that genistein could significantly increase the 
aromatase activity in the ERa-transfected HepG2 cells. Genistein might increase 
apoAl and LDLR by way of estrogen synthesis. This study provided a new insight 
for the gene-regulatory mechanism of genistein, or other estrogen-like compounds. 
Besides, we also demonstrated that TCDD could enhance the aromatase activity 
through a post-transcriptional stabilization of aromatase mRNA in MCF-7 cells. 
Such process could be mediated by ERK. In conclusion, genistein and TCDD could 















1應參與了金雀異黃酮誘導芳香化酶活性中的機制。另外，p38 MAP Kinase抑 
制劑能抑制金雀異黃酮所引發的芳香化酶活性，但不能抑壓其引發的啓動子轉 
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C H A P T E R 1 
GENERAL INTRODUCTION 
1.1 AROMATASE 
Aromatase is a cytochrome P450 superfamily enzyme, which is critical in the 
conversion of androgen into estrogen, i.e. testosterone (CI9) and androstenedione 
(CI9) to estradiol and estrone (CI8) respectively. Estone can be further processed to 
estradiol by 17p-hydroxysteroid dehydrogenase type 1 as shown in Figure 1.1 
(Simpson et al, 1994a; Labrie et al, 2000). 
Aromatase is expressed only in gonads and brain in most vertebrates. However, 
primates also express aromatase in placenta, bone and adipose tissue (Lephart & 
Simpson, 1991; Simapson et al’ 1994b). The principal estrogen source of the 
premenopausal non-pregnant woman is synthesized in the ovary. Other sites of 
estrogen biosynthesis are present throughout the body beyond menopause. The 
estrogen synthesized within these extragonadal sites is probably biologically active 
only at local tissue level (Labrie et al, 1997). These sites include osteoblasts (Bmch 
et al, 1992), aortic smooth muscle cells (Sasano et al, 1999), mesenchymal cells of 
the skin and adipose tissue (Simpson et al, 1997), chondrocytes in bone (Bayard et 
al, 1995); amygdala and the medial basal hyptothalamus in brain (Naftolin et al, 
1975). After menopause, adipose tissue becomes the main source of estrogen (Siiteri 
and MacDonald 1973; Simpson et al, 1997). For the male, estrogen play an 
important role in the lipoprotein synthesis, maintenance of bone mineralization and 
spermatogenesis (Tsai-Morris et al, 1985; Nitta et al, 1993; Morishima et al, 1995, 
Carani et al, 1997; Smith et al, 1994; Bagatell et al, 1994). The level of estrogens 
is far higher within the reproductive tract then in the general blood compartment 
(Hess 2000). It has been estimated that testes account for 15% of circulating estrogen 
(Hemsell et al, 1974). In the testis, aromatase is mainly localized in Leydig cells 
(Carreau et al, 1999). Mutation of aromatase gene causes failure of epiphysical 
fusion, osteopenia and delayed bone age in male (Morishima et al, 1995). Male mice 
with a null mutation in the aromatase gene also exhibit alterations in bone 
histomorphometry (Oz et al, 2000). 
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Estrogen plays an important role in the initiation and development of breast cancer. It 
can stimulate cancer cell growth by triggering estrogen receptor-mediated signal 
transduction, resulting in increased DNA synthesis and cell proliferation (Feigelson 
and Henderson, 1996), Estradiol would interact with plasma membrane estrogen 
receptor (ER), change the regulation of cell cycle and Bcl-2 family protein 
expression (Dickson, 1987; Watson et al, 1999; Leung & Wang, 1999). Estrogen 
metabolites formed by cytochrome P450s may also play a role in the initiation of 
cancer. CYPlAl and CYPIBI hydroxylate 17B-estradiol (E2) at the C-2 and C-4 
positions respectively to form 2-hydroxyestradio 1 (2-OHE2) and 4-hydroxyestradiol 
(4-OHE2). These hydroxylated metabolites can further be oxidized to quinones, 
which are putative tumor initiators (Yager, 2000; Zhu et al, 1998; Cavalien et al, 
1997; Cavalien et al, 2002 and Rogan et al, 2003). Some metabolites retain 
estrogenic activity and generate mutagenic free radicals and cause DNA damage 
(Zhu & Connery，1998). The DNA damaging-effects of estrogen have been observed 
in rat mammary tissues and MCF-7 cells (Zhang et al, 2001; Yared et al, 2002). 
Previously, genistein and estradiol were shown to increase LDLR and ApoAl 
expression in HepG2 cells (Yuen, 2005; Lamon-Fava et al., 1999). As aromatase is a 
critical enzyme to convert androgen into estrogen, this study investigated the effect 
of genistein on aromatase activity and its underlying mechanism in the hepatic cells 
HepG2. On the other hand, environmental toxicants, including TCDD, are thought to 
play a role in breast cancer (Mocarelli and Pocchiari, 1988). The possibility that 
TCDD possesses estrogenic effect should be considered. Due to the functional role of 
aromatase, it may play a role in the TCDD-induced breast cancer. In this study, we 










estrone ^ estradiol 
Estradiol-17p-hydroxysteroid 
dehydrogenase Type 1 
Figure 1.1 Scheme illustrates aromatase act as the final rate-limiting enzyme in the 
conversion of estrogen 
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As aromatase is responsible for the synthesis of estrogens, abnormal expression of 
aromatase may have a significant effect in the development and progression of 
malignancy, particularly in the breast (Simpson et al, 1994a). Previous studies have 
shown that aromatase is expressed in breast cancer tissue probably at a higher level 
than in normal breast tissue (James et al, 1987; Esteban et al, 1992; Santen et al, 
1994; Sasano et al, 1994; Bulum et al, 1993 and Harada, 1997). Based on the 
studies in aromatase-transfected MCF-7 and T-47D cells in vitro and in vivo, 
cellular aromatase can affect the breast cancer maintenance and progression (Santner 
et al, 1993 and Yue et al, 1994). As reviewed by Chen and his colleagues (1999), 
aromatase is expressed mainly in adipose stromal cells and fibroblasts in normal 
breast. However, aromatase is expressed in both stromal and cancer cells, suggesting 
aromatase stimulates breast tumor growth in autocrine and paracrine actions. 
1.2 TISSUE SPECIFIC PROMOTER FOR AROMATASE 
EXPRESSION 
Aromatase is encoded by a single copy of CYP19 gene, localized at chromosome 
15q21.2 (Simpson et al； 1994a; Chen, 1988). Transcriptional regulation of the 
CYP19 gene is complex and tissue specific. In human, the expression of CYP19 is 
regulated by alternative splicing (Harada et al, 1993; Mahendroo et al, 1993; 
Simpson et al., 1994a). Each exon I is flanked by its own unique promoter region 
and is spliced onto a common splice junction immediately upstream of the start of 
translation. Hence, the opening reading frame of each transcript (exon II to X)，as 
well as the CYP19 protein, is identical irrespective of the promoter used and site of 
expression (Figure 1.2 B). Up to this date, CYP19 is the only member of the 
cytochrome P450 gene superfamily. A schematic representation of the aromatase 
gene is shown in Figure 1.2. A. 
In CYP19, there are ten distinct tissue-specific promoters: PI.l (placenta, major), 
PL2 (placenta, minor), PI.3 (adipose/ breast cancer), PI.4 (skin and adipose), PI.5 
(fetal tissue), PL6 (bone), PI.7 (endothelial), Pl.f (brain), PII (ovary/breast 
cancer/endometriosis) and P2a (placenta, minor) (Shozu et al., 1998; Sebastian et al.’ 
2001; Sebastian et al, 2002) (Figure 1.2 A). In breast cancer, exons 1.3 and II are the 
most frequently used, suggesting the promoter 1.3 and II are the major promoters 
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directing aromatase expression in the malignant and surrounding tissue (Zhou C., et 
al, 1996). This is different from exon 1.4 used by the adipose stromal cells and 
fibroblasts in normal breast (Harada, 1993; Mahendroo et cd” 1993). 
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(A) 
Exon(s) I II III IV V VI VII VIII IX X 
- ^ — S I I [ J E ~ ~ 一•^捕LJ-
Tissue specific AATAA 
U 2a 1.4 1.5 1.7 l.f 1.2 1.6 1.3 Pll Exonll 
Common SpHceSitein Exon II start of translation (Avj/GAO I) 
(B) 丨5’-UTf^  Identical coding region ^ 
AATAA 
Exon(s) 1 II III IV V VI VII VIII IX X ^ 
Tissue CYP19 Transcripts Detected 
Figure 1.2. A. A schematic representation of the aromatase gene. A CYP19 overview 
shows the exons and multiple sub regions of exon I. Figure B illustrates that the 
coding region and the translated protein product are identical in all tissues, even 
though each tissue expresses a unique untranslated first exon 5'UTR. Dark gray 
shading, translated region; light gray shading, untranslated region; Black shading, 
common untranslated region. (Modified from Sebastian et al, 2001 and Ellem et al, 
2004) 
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1.3 SIGNALING PATHWAY 
MAP kinase is involved in the regulation of diverse processes ranging from 
transcription of protooncogenes to programmed cell death (Cobb, 1999). The MAPK 
cascade is generally sub-classified into three main branches: p38 kinases, c-Jun N-
terminal kinases (JNKs), and extracellular signal-regulated kinases (ERKs) 
(Garrington and Johnson, 1999; Torres, 2003). Upon activation, a series of 
successively acting kinase would amplify signals that regulate diverse biologic 
functions, including cell growth, differentiation, proliferation and apoptosis 
(Molkentin, 2004). Generally, JNK and p38 kinase pathways may serve as 
transducers for injury or stress responses, whereas ERK pathways are more 
specialized for growth and mitogenic factor stimulation (Garrington and Johnson, 
1999). Figure 1.3 illustrates a simplified scheme of MAPK signaling pathway. After 
signal coming at the cell membrane activates the Ras protein, Ras would directly 
couple to Raf and phosphorylates MEKl/2. These two proteins act as dual specificity 
kinases and directly phosphorylate the TEY motif in ERK 1/2 kinases. Similar 
cascades have been observed in JNK and p38 kinase pathways. MKK4/7 can be 
activated by MEKK and then phosphorylate JNKl/2/3’ while MKK 3/6 directly 
activate the genes, p38a, p38p, p38S, andp38y (Garrington and Johnson, 1999). 
cAMP-dependent protein kinase, which is also known as protein kinase A (PKA), is 
allosterically activated by cAMP. The inactive form of PKA consists of two 
regulatory and two catalytic subunits. When cAMP binds to the regulatory subunit, 
the regulatory subunit would undergo conformational changes and yield two catalytic 
subunits. They in turn phosphorylate many enzymes at Ser or Thr sites, including 
CREB, glycogen synthase, phosphorylase b kinase and tyroine hydroxylase. Protein 
kinase C (PKC) is activated by elevated concentration of calcium. Phorbol esters, 
which are tumor promoters, are potent activators of PKC and affect the normal 
regulation of cell growth and division. Similar to PKA, PKC phosphorylates Ser or 
Thr residues of specific target protein and alters its catalytic activities (David, 2000). 
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Transcriptional factor Elk-1, c-Myc etc c - ]m, ATF-2 etc ATF-2, Max etc 
\ / \ 1 / \ / 
Growth Growth Cytokine production 
Cellular response differentiation differentiation apoptosis 
survival 
apoptosis 
Figure 1.3 A simplified scheme illustrates MAPKs signaling pathway. 
(Modified from Garrington and Johnson, 1999) 
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C H A P T E R 2 
MATERIALS AND METHODS 
2.1 CHEMICALS AND MATERIALS 
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) was purchased from Supelco. The mitogen-
activated protein (MAP) kinase inhibitor U0126, p38 MAP kinase inhibitor SB203580, 
the protein kinase A (PKA) inhibitor myristoylated 14-22 amide and the protein kinase 
C (PKC) inhibitor bisindolylmaleimide I were obtained from Calbiochem (San Diego, 
CA). 
ICI 182 780 was a gift from Dr. Y. Huang (Physiology Department, the Chinese 
University of Hong Kong, HKSAR, China). All other chemicals, if not stated, were 
acquired from Sigma Chemical. 
2.2 MAMMALIAN CELL CULTURE 
Two ER-positive human breast cancer cell lines MCF-7 and T47D, two ER-negative 
breast cancer cell lines SK-BR-3 and MDA-MB-231, a ER-negative hepatocellular 
carcinoma cell line HepG2 and a non-tumorigenic breast cell line MCFIOA were used in 
the present study. SK-BR-3 cells were generously given by Dr. Richard K.W. Choy 
(Department of Obstetrics & Gynaecology，the Chinese University of Hong Kong, 
HKSAR, China). MCF-7 cells stably transfected with human CYP19 (MCF-7aro) or 
empty vector (MCF-7vec) were kindly provided by Dr. S. Chen (Department of Surgical 
Research, Beckman Research Institute of the City of Hope, Duarte, CA91010, U.S.A.). 
MCF-7 cells stably transfected with ERK (MCF-7ERK) were prepared in our lab by other 
postgraduate student. All other cell lines were purchased from American Type Cell 
Collection (Rockville, MD，USA) 
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2.2.1 Maintenance of cells 
MCF-7, MDA-MB-231, T47D, MCF-7aro, MCF-7ERK and MCF-7vec were maintained in 
RPMI 1640 media, and the later two medium contained 500|a.g/ml selection antibiotics 
G418 (USB, Cleveland, OH, USA). HepG2 and MCFIOA cells were maintained in 
phenol red free RPMI 1640 media and DMEM/F12 media (Gibco BRL, Rockville, MD, 
USA) respectively. All media were supplemented with 2 mol/L L-glutamine (Gibco 
BRL, Rockville, MD, USA), 1% Penicillin-Streptomycin (P/S) (Gibco BRL, Rockville, 
MD，U.S.A) and 10% fetal bovine serum (FBS) (Hyclone). SK-BR-3 cells were 
maintained in McCoy's 5A medium with 2 mol/L L-glutamine and 12.5% FBS. All the 
cell lines were incubated at 37°C, 5% carbon dioxide. 
When cells reached about 80% confluence，the medium was discarded. The cell was 
washed with PBS and was trypsinized with trypsin-EDTA (Invitrogen) for 5 minutes. 10 
minutes trypsinization was required in MCFIOA cells. The cell suspension was 
transferred to a 15ml centrifuge tube containing 7ml PBS and centrifuged at 1,000 rpm 
at room temperature for 5 minutes. The cell pellet was resuspended with fresh growth 
medium, added in aliquot into new culture flasks and incubated as described above. 
Phenol red is known to contain an estrogenic contaminant. Starting from the beginning 
of each assay, the cells were seeded with phenol-red free RPMI 1640 with 2 mol/L L-
glutamine，1% Penicillin-Streptomycin (P/S) and 5% charcoal/dextran treated fetal 
bovine serum (FBS) (Hyclone). 
2.2.2 Preparation of cells stock 
Semi-confluent cells in culture flask were rinsed with PBS and trypsinized as described 
above. After the centrifugation, the cell pellet was resuspended in 500|al of growth 
medium and transferred into a 2m 1 freezing tube containing 500|il of FBS and 200|j.l 
DMSO. The tubes were put inside an isopropanol filled freezing pot (Nalgene, USA). 
The pot was put into a -80 freezer so that the cell stock was frozen at a constant rate 
of nearly 1 °C / min. The frozen vials were stocked into liquid nitrogen for permanent 
storage. 
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2.2.3 Cell recovery from liquid nitrogen stock 
The cell stock was taken out from the liquid nitrogen tank and thawed at once in a 37°C 
water bath. The cells were plated on a 60mm dish or a 25cm^ culture flask with 
appropriate fresh growth medium. The cells were incubated at 37°C, 5% carbon dioxide. 
Due to the toxicity of DMSO, fresh medium was replaced after 6 hours incubation. 
2.3 TRITIATED WATER RELEASE ASSAY 
The aromatase enzyme activity was measured based on the tritiated water release assay, 
which measured the amount of tritiated water produced during the conversion of 
androstenedione to estrone by aromatase. As shown in the Figure 2.1, three molecules of 
NADPH and oxygen were required for each estrogen formed during the process. The 
final hydroxylation resulted in a loss of Ip-^H of the androstenedione into the aqueous 
phase of the reaction. Then, it generated the tritiated water. The conversion rate 
determined by the isolation and the quantification of tritiated water represented the 
aromatase activity (Lephart & Simpson, 1991). 
2.3.1 Aromatase Activity in Intact Cell 
Cellular aromatase assays were performed as previously described (Ciolino et al., 2000). 
In short, cells were seeded in 6-well plates at a density of 5 x 10^  per well for 24 hours. 
Tested compounds were administered with appropriate time points. The substrate [ip-
^H(N)]-androst-4-ene-3,17-dione (23.5 Ci/mmol, Perkin Elmer, Boston, MA, USA) in 
1ml of serum-free medium after cells were rinsed with PBS. The final concentration of 
substrate was controlled at 25riM. The reaction was incubated for 1 day at 37°C. Similar 
protocol was applied to assays performed on SK-BR-3, MCF-7aro and MCF-7vec cells, 
except that they were incubated with the substrate for 3 hours. 
The medium was then removed and mixed with 1ml of chloroform. The mixture was 
then centrifuged at 10,000 x g at 4°C for 10 minutes to remove the unreacted substrate. 
500|j.l of aqueous phase, which containing the tritiated water, was removed into a new 
eppendorf containing 500}j.l of 5% activated charcoal suspension. After 30 minutes 
incubation at room temperature, it was centrifuged at 15, 000 x g for 15 minutes. 625fil 
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of the supernatant fraction was transferred into vial with 2.5ml scnillation cocktail 
(Perkin Elmer) for the counting (Beckman，Fullerton, CA, USA). 
On the other hand, the protein content of the cells was determined by using BCA kit 
after dissolving the cells in 300)J.1 of O.5mol/L NaOH. Results were expressed as 
radioactive counting recorded per hour per mg protein. 
2.3.2 Aromatase assay on recombinant supersomes 
In addition to the "in-cell" assay, aromatase assay was also performed on recombinant 
aromatase expressed in insect microsomes (human CYP 19 Supersomes®，Gentest Corp, 
Woburn, MA, USA). Similar experimental procedures were applied except that the cells 
were replaced by the recombinant protein (Ciolino et al, 2000). The assay performed in 
a total volume of 250|il with the following additions: 25riM [ 1 p-^H(N)]-androst-4-ene-
3,17-dione, 2pmol Supersomes®, 3.3mM MgCb, lOOmM KH2PO4 (pH 7.4)，2.5|LI1 of 
testing compounds and 1.3mM NADPH. The reaction was initiated by adding NADPH 
and incubated at 37�C for 15 minutes. The reaction was stopped by adding 1.4ml of 
chloroform and 0.35ml 0.9% NaCl. After vortexing and centrifugation at 10,000 x g for 
10 minutes, 400|il of the aqueous phase was removed and mixed with 400}aJ 5% 
activated charcoal in a new eppendorf tube. The charcoal-contacting aqueous extract 
was then vortex and incubated for 30 minutes at room temperature. The tubes were 
centrifuged at 15，000 x g at at 4°C for 15 minutes. 625p-l of the supernatant fraction was 
transferred into vial with 2.5ml scnillation cocktail for the counting. 
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2.4 R N A ISOLATION AND CDNA SYNTHESIS 
Total RNA was isolated from cells grown in 12-well plates by TRIzol Reagent as 
directed by manufactures (Invitrogen Corp., California, USA). The concentration and 
purity of RNA were determined by spectrophotometry at 260/280nm. The integrity of 
RNA was assessed by agarose gel. 
3|j.g of total RNA was denatured at 70°C for 5 minutes with 0 . 0 2 5 o l i g o - d T 
(Invitrogen). The samples were chilled on ice quickly. Complementary DNA (cDNA) 
was synthesized by using 100 units M-MLV Reverse Transcriptase (USB Corporation), 
IX M-MLV reaction buffer and 0.5mM dNTP mixture in a total volume of 20ul. The 
contents was mixed and incubated at 37°C for 60 minutes and consequently inactivated 
at 70°C for 10 minutes. The cDNA generated was used as a template in PCR and real-
time PCR. 
2.5 SEMI-QUANTITATIVE P C R REACTION 
The reaction mixture was set up as follows: 
Sterile dUjO (16-x) |il 
lOX PCR reaction buffer with 50mM MgCh ^ 
lOmM dNTP 0.4^1 
10|xM Forward primer 0.4|4,1 
lOjiM Reverse primer 0.4fjJ 
Template cDNA x |il 
Taq DNA polymerase (5U/)il) 0.2)il 
Total 20\x\ 
The primer sequences are listed in Table 2.1. 20 PCR cycles were performed for p actin 
and 40 cycles for aromatase exon I of amplification were performed with a denaturation 
temperature 94°C for 30 second. The annealing temperatures for p actin and aromatase 
exons were 60°C and 55°C respectively, followed by extension temperature of 72°C for 
30 seconds. When the reaction was completed, the reaction mixture was analyzed by 
1.5% agarose gel electrophoresis. 
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A Gene and oligonucleotide Sequence 
P actin forward TCA CCC ACA CTG TGC CCA TGT ACG A 
(3 actin reverse CAG CGG AAC CGC TCA TTG CCA ATG G 
CYP 19 reverse CTG ACA GAG CTT TCA TAA AGA AGG G 
(common antisense primer) 
B Gene and oligonucleotide Sequence 
1.1 forward TGT GCT CGG GAT CTT CCA GAC 
1.2 forward TTC CAT TTC AGA TAT TCC CA 
1.2 reverse ATC CAT GGC TTG CTT GA 
1.3 forward GGG CTT CCT TGT TTT GAC TTG TAA 
1.4 forward AAC GTG ACC AAC TGG AGC CTG 
1.5 forward TTT GGA CAG TGG GCA CAG AG 
1.6 forward AGA CTA CCT ACC ATC CCT GAA A 
1.7 forward GGC TCC ATC TAG AAG GAT GA 
I.f forward TTA TAA AAG ATG GCA CAC GAA 
2a forward TGA AAT TCA GCC TGT GGA TT 
II forward CTC TGA AGC AAC AGG AGC TAT AGA T 
Table 2.1 Primer sequences for (A) p actin and CYP 19; (B) CYP 19 multiple exon I 
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2.6 QUANTITATIVE REAL TIME P C R USING TAQMAN 
PROBE 
The target mRNA levels were determined by real-time PCR using the OpticonTM 2 
System (MJ research, Waltham, MA, USA). The primers and FAM-labelled probes of 
CYP19, four CYP19 exons and internal control GADPH were all purchased from 
Applied Biosystems (Table 2.2). 
The reaction mixture consisted of lOjoi Taqman Universal PCR Master Mix (EastWin), 
lul FAM-labelled probe and 2|il cDNA in a final volume of 20|xl. The thermocycling 
profile was 5(fC for 2 minutes, 95°C for 10 minutes and 45 cycles of 95�C for 15 second 
and 60°C for 1 minute. The target and reference genes were amplified in separate wells. 
All samples were run in triplicate. 
The gene expression of samples relative to control is determined by method 
(Livak & Schmittgen，2001). The mean fold change in expression of target gene 
compared with control was calculated with the equation: 
Relative target gene expression = 2'道丁 
where A A C T = (CTtarget — C T house keeping) sample “ (CTtarget 一 C T house keeping) control 
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Assay No CYP19-F165 
Forward primer~~GGAGAATTCATGCGAGTCTGGAT 
CYP19 
Reverse primer GGAACATACTTGAGGACTTGCTGAT 
Reporter TCTGGAGAGGAAACACTC 
Assay No EXONIA.l-JUN 
Forward primerCTGTGCTCGGGATCTTCCA 
Exon LI 
Reverse primer CATCTTGTGTTCCTTGACCTCAGA 
Reporter ACGTCGCGACTCTAAAT 
Assay No EXONI3-J68 
Forward primerAAATTAGTCTTGCCTAAATGTCTGATCACA 
Exon 1.3 
Reverse primer CCAAAACCATCTTGTGTTCCTTGAC 
Reporter TTATAAAACAGACTCTAAATTGCC 
Assay No EXONI4-J60 
Forward primerGTCCCTGGCACTGGTCAG 
Exon 1.4 
Reverse primer CATCTTGTGTTCCTTGACCTCAGA 
Reporter CCCATCAAACCAGGACTC 
Assay No EXONII-J79 
Forward primer~~GCAACAGGAGCTATAGATGAACCTT 
Exon II 
Reverse primer CATCTTGTGTTCCTTGACCTCAGA 
Reporter CCACAGGACTCTAAATTG 
Assay No EXONIA-J212 
Forward primer~~CCGCACACACAAAGCAACATTT 
Exon 2a 
Reverse primer CATCTTGTGTTCCTTGACCTCAGA 
Reporter CCTGTGGACTCTAAATTG 
Table 2.2 The forward primer, reverse primer and reporter sequences of CYP19 Taqman 
probes (Applied Biosystems). 
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2.7 WESTERN BLOTTING 
5 X 10^  cells per well in a 6-well plate were seeded in RPMI 1640medium containing 5% 
charcoal/dextran treated FBS. After transfection of 0.7|xg of expression vectors 
(pcDNA3.1 or pcDNA3.1- ERa) and/ or drug treatment for 2 days, the cells were 
harvested. Cells were rinsed with PBS and lysed by 50|il RIPA lysis buffer (25mM Tris-
HCl pH 8.8, 50mM NaCl, 0.5% NP40, 0.5% Deoxycholate, 0.1% SDS). Then, the cells 
were scraped off with a cell disrupter. The lysates were then sonicated by a cell disrupter 
(Branson Ultrasonics Corp., Danbury, CT, USA) on ice for 10 seconds. It was then 
centrifuged at 4°C for 5 minutes. The supernatants were transferred into a new 1.5ml 
eppendorf for immediately use or storing at -80�C for long term storage. 
Protein concentration of the supernatant was determined by Bicinochonic Acid Assay 
with bovine serum albumin (BSA) as standard. 50ug of sample protein was separated on 
12.5% SDS-PAGE and transferred to an Immobilon PVDF membrane (Millipore, 
Bedford, MA, USA) for 90 minutes at 15V. The membrane was incubated in 5% non-fat 
milk powder in PBS for at least one hour at room temperature. Then, it was incubated in 
primary antibody overnight at 4°C. The membrane was washed three times with TBS/T. 
Then, the membrane was incubated with secondary antibodies conjugated with 
horseradish (Armoracia rusticana) peroxidase (Santa Cruz Biotechnology, Inc.) for at 
least one hour at room temperature. The Westsave Up™ (Labfrontier, Ewha University, 
Seoul, Korea) provided the chemi-luminence substrate for horseradish peroxidase. The 
targeted protein was visualized by exposure to X-ray film (Kodak, Rochester, NY, USA), 
p-actin was used for protein normalization. 
Primary Antibody Working dilution Purchased by 
P actin 1:5000 Sigma Chemical Co 
Aromatase 1:400 Abeam, Cambridge, UK 
pERX 1/2 1:250 Santa Cruz Biotechnology, Inc. 
ERK 1/2 1:1000 Zymed Laboratories, South San Fransicso 
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2.8 MEASUREMENT OF PROMOTER ACTIVITY 
2.8.1 Plasmid Preparation 
The human ERa expression vector (pcDNA3.1-ERa), reporter plasmids for 
apolipoprotein A1 promoter, aromatase promoter I.l and I.3/II were made in our lab by 
other postgraduate student. The pGL-3 basic reporter vector and AP-1 luciferase reporter 
plasmid were purchased from Promega and Clontech (Palo Alto, California, USA) 
respectively. ERE-luciferase reporter plasmid C3-LUC was a gift from Dr. Donald 
McDonnell (Duke University, NC, USA). 
2.8.2 Transient Transfection and Dual Luciferase Assay 
1 X 10^  cells were seeded in 24 well plate in RPMI 1640medium containing 5% 
charcoal/dextran treated FBS. In MCF-7, 0.2ug reporter plasmid (containing DNA 
fragments derived from aromatase promoter region) were pre-complexed with 2.5|a,l 
PLUS reagent and diluted into 25|il serum-free medium. The Renilla luciferase vector 
pRL-CMV (Promega) was cotransfected as an internal correction for transfection 
efficiency. Similar components are found in the transfection of HepG2 cells, except 
0.2|ig expression vectors (pcDNAS.l or pcDNA3.1- ERa) and l.S^il PLUS reagent were 
added in the reaction. The mixture was incubated at room temperature for 15 minutes. In 
a second tube, \\i\ of LIPOFECTAMINE Reagent was diluted into 25|^ 1 medium without 
serum. It was mixed and incubated at room temperature for further 15 minutes. The cells 
were replaced with 200|LI1 erum free RPMI 1640 medium. The DNAs-PLUS-
LIOPFECTAMINE Reagent complexes were added into each well medium. After 4 
hours incubation, cells were cultured in RPMI 1640medium containing 5% 
charcoal/dextran treated FBS. After one day, various concentration of testing 
compounds were added and incubated for 48 hours. The cells were lysed in 100|il lysis 
buffer (Promega). The cell lysates were stored at -80°C until assay. Dual Luciferase 
assays were performed according to manufacturer's instruction (Promega). By using a 
FLUOstar Galaxy plate reader (BMG Labtechnologies, Offenburg, Germany), the 
luciferase activity was read and expressed as relative light units of firefly/renilla. 
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2.9 STATISTICAL METHODS 
A Prism® 3.0 (GraphPad Software, Inc., CA, USA) software package was utilized for 
statistical analysis. The results, whenever applicable, were analyzed by two-tailed 
Student's t-test to determine if significant (P<0.05) difference observed. 












































































































C H A P T E R 3 
GENISTEIN UP-REGULATES AROMATASE IN ESTROGEN 
RECEPTOR ALPHA-TRANSFECTED HEPG2 CELLS 
3.1 INTRODUCTION 
3.1.1 Cardiovascular diseases (CVD) 
Diseases of the heart and blood vessel are collectively known as cardiovascular 
disease (CVD). CVD has been a leading cause of global morbidity and mortality and 
is responsible for one-in-three deaths. Recent projections suggest that CVD will be 
the leading cause of death in both developed and developing regions of the world by 
2020 (Murray and Lopez, 1996). From 1981 to 2006，diseases of the heart were the 
second killer disease in Hong Kong (Department of Health, 2007). Epidemiologic 
studies have connected the consumption of an isoflavonoids-rich diet with a lower 
incidence of CVD (Adlercreutz, 2002). In normal postmenopausal women, dietary 
inclusion of whole soy foods containing 60 mg/d of isoflavones results in reductions 
in several key clinical risk factors for CVD (Scheiber et al, 2001). Japanese men 
who consume large amounts of soy have nearly one-six the risk of CVD as their 
counterparts in America (Beaglehole, 1990). Other research group has also illustrated 
the inverse association between soy product intake and heart disease in Japan 
(Nagata, 2000). 
3.1.2 Phytoestrogen 
Phytoestrogens are widely studied in the mechanism in the prevention of cancers, 
heart disease, menopausal symptoms and osteoporosis (Setchell, 1998; Adlercreutz, 
2002; Kronenberg and Fugh-Berman, 2002). High intake of dietary phytoestrogen 
may account for the lower rate of CVD in Asia than that in other Western country 
(Tikkanen and Adlercreutz, 2000; Tham et al, 1998). Phytoestrogens are plant-
derived chemicals, which have chemical structures similar to the mammalian 
estrogen 17P-estradiol (E2) (Price and Fenwick，1985; Knight and Eden, 1996; 
Mazur, 1998). They can be classified according to their differences in structure and 
functional group. One of the major classes of phytoestrogen is isoflavone, which has 
been the focus of many in vitro, in vivo and clinical research studies in relation to 
their health effects (Kingsbury, 1969). 
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The aromatic ring and the hydroxyl group of phytoestrogens are important for the 
binding to the estrogen receptors (ER) (Anstead et al, 1997). The A and C rings of 
the isoflavones are similar to the A and H rings of estrogen (Figure 3.1.1). The 
phytoestrogens trigger both anti-estrogenic and estrogenic activities in the body. As 
estrogen antagonists, they may block or alter the ER binding and thus abolish 
estrogenic activity. On the other hand, they can mimic the effect of endogenous 
estrogen (Brzezinski and Debi, 1999). Based on their binding affinities to ER, the 
estrogenic activities of phytoestrogens are around 1/500 to 1/1000 of that of estrogen 
(Jefferson et al, 2002; Joung et al, 2003). Due to the slight structural differences 
among various phytoestrogens, the binding affinities towards isoforms of ER are also 
different. Among the soy isoflavones, genistein has the greatest binding affinitiy to 
ERa (Latonnelle et al, 2002). 
In this study, genistein, which is a major isoflavone isolated from soy bean, was 
investigated (Cheng E et al； 1953). Soy beans have been reported in ancient Chinese 
herbals for the healthy functioning of the heart, kidneys, liver and stomach (Duke 
and Ayensu, 1985). Its structure is shown in Figure 3.1.1 C. Genistein is found as its 
glycosides in plants (Ibarreta et al, 2001). They are readily degraded by gut enzymes 
to form aglycone and absorbed to the bloodstream. The plasma level of genistein in 
individuals consuming a high soy-containing diet was estimated as to be l-4|xmol/l 
(Adlercreutz et al., 1995)，or 0.1|xmol/l in vegetarian women (Adlercreutz et al, 
1993). Though there has not been an extensive examination, the concentration of soy 
isoflavone in our body fluids is likely in the micromolar range. 
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Figure 3.1.1 Structure of 17p-estradiol and isoflavones 
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3.1.3 Estrogen receptor 
Estrogen receptor (ER) is a ligand-dependent nuclear receptor which involves in 
transcriptional regulation. There are two isoforms of ER: ERa and ERp (Kong et al, 
2003). The three-dimensional arrangements of these isoforms are identical. However, 
in ERp, 96% of DNA binding domain and 58% of ligand binding domain are similar 
with those in ERa (Mosselman et al, 1996). ERa is found in various tissues, 
including bone, breast, heart and central nervous system. Both receptors are 
expressed in liver, but ERa is expressed more than ERP (Gustafsson, 1999). 
ERa is a member of nuclear hormone receptor which may bind a wide range of 
hydrophobic molecules, including steroid hormone, phytoestrogens and tamoxifen. 
The most common ligand is estrogen. Originally, more than 80% of ERa is localized 
in the nucleus. Upon estrogen stimulation, ERa is increasingly localized in the 
nucleus (Ylikomi et al, 1992). The activation of ER depends on the ligand, dosage 
and tissue type. Raloxifene has shown an antiestrogenic effect in breast cancer tissue 
and the brain. On the other hand, it shows estrogen-like actions in bone and 
cardiovascular system. 
Before being activated, heat shock proteins in dimeric forms block the DNA-binding 
domain of ERa so as to prevent the association of the receptor with DNA. Once the 
ligands bind to C-terminal domain of ERa, there is a conformational change of the 
receptor. The heat shock proteins would be released. The activated ERa, which is in 
its dimerized state, is translocated through nuclear pore into nucleus. After binding to 
estrogen response element (ERE), transcriptional coactivators (SRC-1) and 
cointegrators (p300/CBP) also interact with the complex. Transcription is activated 
and mRNA encoded by the gene is expressed (Parker et al, 1993; Klinge, 2001). 
ER can also activate gene transcription indirectly with promoter specific elements 
(Pettersson and Gustafsson, 2001). In some genes, estrogen has been shown to 
promote transcription through AP-1, a binding site for Fos and Jun (Webb et al., 
1995). In addition, ERa interacts with Spl and binds to Spl sites in LDLR promoter 
to enhance the transcription and translation of LDLR (Yien et al, 1995). The 
interaction between ERa and Spl does not require the DNA-binding domain of ERa. 
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ER can also regulate gene expression in a ligand-independent manner by modulating 
several secondary signaling pathways. ICI 182 780, an estrogen antagonist, can 
abolish the 17p-estradiol-stimulated c-fos expression through the MAPK pathway 
(Hennessy et al, 2005). Some non-genomic pathways can be activated by MAP 
kinase and PKA (Klinge et al, 2005; Katzenellenbogen, 1996; Weigel and Zhang, 
1997). Hence, the latter mechanisms of ER action enable a broader range of genes to 
be regulated other than the classical ER action. 
3.1.4 Protective mechanism against CVD protective 
Reducing platelet aggregation, inhibiting expression of tissue factor gene and 
lowering serum cholesterol would help to protect our bodies from getting CVD. High 
density lipoprotein (HDL) cholesterol lowers the serum cholesterol by reverse 
cholesterol transport (Mayne and Mayne, 1994; Fielding and Fielding, 1995; 
Breslow, 1995). Low density lipoprotein (LDL) cholesterol accounts for about 70% 
of the total cholesterol in plasma. It is regarded as bad cholesterol as it increases the 
serum cholesterol (Mayne and Mayne, 1994). Hence, increased HDL cholesterol and 
decreased LDL cholesterol are believed to lower the CVD risk. Serum LDL-
cholesterol and HDL-cholesterol can be regulated by LDL receptor (LDLR) and 
apolipoprotein A-I (apoAl) respectively (Cortese et al, 1983; Zabalawi et al,, 2003). 
LDL is taken up by specific LDL receptors (LDLR), which are most abundant in the 
liver cell surface. LDLR recognizes apoB and apoE on LDL. The receptor-LDL 
complex would be internalized by endocytosis. The LDL particles would be broken 
down by lysosome after entering the cells. LDLR would return to plasma membrane 
and bind to another LDL. Hence, increasing the rate of LDLR synthesis would 
reduce the amount of intracellular cholesterol. 
ApoAl is the major protein of HDL. ApoAl plays an important role in the reverse 
cholesterol transport pathway by activating LCAT for cholesterol esterification. It 
also interacts with ATP binding cassette transporter Al cell membrane receptor and 
thus promotes cell cholesterol efflux. It carries the excess esterified cholesterol back 
to the liver for excretion (Rader，2002). 
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3.1.5 Effects of genistein on LDL Receptor and Apolipoprotein A-I 
Many research groups have studied the relationship between phytoestrogens and 
LDLR. Dietary isoflavones reduce plasma cholesterol and atherosclerosis in 
C57BL/6 mice but not LDL receptor-deficient mice (Kirk et al, 1998). Soy protein 
with intact isoflavones has shown to increase serum HDL concentration (Sanders et 
al, 2002). 
Our group has investigated the effect of genistein on LDLR and apoAl. Similar to 
previous findings (Borradaile et al, 2002; Lamon-Fava et cd., 2004; Lamon-Fava, 
2000), genistein was shown to up-regulate LDLR and ApoAl expression through an 
ERa-dependent transcriptional control in HepG2 cells (Yuen, 2005). Lamon-Fava's 
group (2000, 2004) have suggested that the increase of apoAl gene expression is 
probably not through the classical ER/ligand genomic activation. It may be due to the 
binding of transcriptional factors to -256 to -41 region of the apoAl promoter. 
However, the underlying mechanism has not been fully elucidated. 
3.1.6 Effects of estradiol on LDL Receptor and Apolipoprotein A-I 
It is widely accepted that estrogen is critical in the prevention of CVD. According to 
a recent statistical figure from American Heart Association (2004), males have a 
higher rate of prevalence of CVD than females. Postmenopausal women have 2 
times higher CVD incidence rate than premenopausal women at the same age in 
another study (Kannel et al, 1976). The serum LDL-cholesterol levels decrease after 
treatment of aromatase inhibitor in men (Bagatell et al., 1994). 
17p-estradiol (E2) is the major form of estrogen, and has been shown to up-regulate 
apoAl and LDLR in HepG2 cells. ApoAl promoter transcription can be induced by 
4-fold in the presence of 10p,M E2 in HepG2 cells (Lamon-Fava et al, 1999). 
Previously, our group has demonstrated that ERa is important in the gene regulation 
of LDLR and apoAl under the physiological level of E2 in HepG2 cells (Yuen, 
2005). Incubation of HepG2 with E2 increases cell surface LDLR activity 
significantly in vitro (Semenkovich and Ostlund, 1987; Owen et al., 2004). The 
mechanism could be upregulated through ERa (Bruning et al, 2003) and tyrosine 
kinase (Distefano et al, 2002) in these cells. 
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3.1.7 Aim of study and hypothesis 
Though the interaction between genistein and LDLR or apoAI has been widely 
studied, the mechanism has not been fully elucidated. A schematic representation of 
the effect of genistein is shown in Figure 3.1.2. Genistein and estradiol were shown 
to increase LDLR and ApoAl expression in HepG2 cells (Yuen, 2005; Lamon-Fava 
et al, 1999). On the other hand, aromatase is a critical enzyme to convert androgen 
into estrogen in the body. Many researches have studied the effect of genistein on 
aromatase activity in other tissues, especially breast cancer tissue. lOjiM genistein is 
found to inhibit aromatase in MCF-7 cells (Brooks and Thompson, 2005). Hence, 
this study investigated the effect of genistein on aromatase activity and its underlying 
mechanism in the hepatic cells HepG2. If genistein could regulate aromatase in 
HepG2 cells, it might alter the amount of E2, and consequently affected LDLR and 
apoAl expression. The current objective was concentrated on the effect of 
ER/genistein on the transcriptional control of aromatase. 
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Figure 3.1.2 Schematic representation of the hypothesis on the estrogenic effect of 
genistein. 
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3 . 2 RESULT 
3.2.1 ERa increased Aromatase Activity in HepG2 cells 
Aromatase activity in the untreated cells was 10.315 士 2.9628 cpm/ |ag protein/ hour, 
and the activity was elevated to 386.445 士 10.3733 cpm/ fig protein/ hour after 
transfected with ERa. Figure 3.2.1 showed that the activity in cells transfected with 
empty vector had no difference compared to the untreated one. The activity in ERa-
transfected cells elevated significantly, approximately 37 times higher than that in 
the untreated cells. 
3.2.2 Genistein increased aromatase activity in HepG2 cells 
To determine the regulation of aromatase activity in HepG2 cells, we transfected the 
cells with ERa, and incubated the cells with various time points and concentrations 
of genistein. Aromatase activity was assessed using the tritiated H2O release method 
(Lephart & Simpson, 1991). Effect of lOjiM genistein on the aromatase activity in 
HepG2 cells was investigated over a 48 hour period (Figure 3.2.2). lOjiM genistein 
would increase the aromatase activity after more than 24 hours. In the presence of 
ERa, the aromatase activity was induced significantly, nearly 10 fold higher than that 
in the absence of ERa. Aromatase activity was significantly induced as early as 6 
hours and reached a maximum at 48 hours after the addition of genistein. Hence, in 
the following experimental design, the cells would be treated with genistein for 48 
hours. 
Genistein could induce the aromatase activity in a dose-dependent manner in HepG2 
cells (Figure 3.2.3). It induced the activity by 50% at lOjiM and such induction could 
be abolished by estrogen antagonists ICI 182 780. In the presence of ERa, genistein 
could increase aromatase activity in a dose-dependent manner. Genistein induced the 
activity by 200% at 0.1 |iM while over 3-fold increase was observed at 10|iM (Figure 
3.2.4). Such induction could be suppressed by ICI 182 780 (Figure 3.2.5). 
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Figure 3.2.1 Aromatase activity in HepG2 cells. HepG2 cells were transfected with 
ERa expression vector and control plasmid pcDNAS.l. The cells were further 
incubated with 25r|M [lp-^H(N)]-androst-4-ene-3,17-dione for 24 hours. Aromatase 
activity was determined by using tritiated water release assay. Values are means 
士SEM, n=3. (***P<0.0005) 
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Figure 3.2.2 Time course of genistein stimulation of the aromatase activity in 
cultured HepG2 cells. Cells were transfected with ERa expression vector and control 
plasmid pcDNAS.l, and treated with \0\iM genistein for 6, 24 and 48 hours. The 
cells were further incubated with 25r|M [lp-^H(N)]-androst-4-ene-3,17-dione for 24 
hours. Aromatase activity was determined by using tritiated water release assay. 
Values are means 士SEM，n=3. Symbols a to e are used for the lOjiM genistein group 
and the order is e > d >c >b > a. Symbols x and y are used for the DMSO group and 
the order is y > x. (*/ # P<0.05; **P<0.005) 
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Figure 3.2.3 Dose-dependent elevation of aromatase activity induced by genistein in 
HepG2 cells. The cells were pretreated with l|xM ICI 182 780 for 3 hours before 
adding genistein for further 48 hours. The cells were further incubated with 25r|M 
[1 p-^H(N)]-androst-4-ene-3,17-dione for 24 hours. Aromatase activity was 
determined by using tritiated water release assay. Values are means 士SEM, n=3. * 
represents values different from control; # represents values different from lO i^M 
genistein. (*P<0.05; **P<0.005; ###P<0.0005) 
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Figure 3.2.4 Dose-dependent elevation of aromatase activity induced by genistein in 
ERa-transfected HepG2 cells. Cells were transfected with ERa expression vector and 
control plasmid pcDNAS.l, and treated with lOjiM genistein for 48 hour. The cells 
were further incubated with 25riM [ 1 p-^H(N)]-androst-4-ene-3,17-dione for 24 hours. 
Aromatase activity was determined by using tritiated water release assay. Values are 
means 土SEM，n=3. (*P<0.05; **P<0.005) 
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Figure 3.2.5 Effect of l|xM ICI 182 780 on genistein-induced aromatase activity in 
ERa transfected HepG2 cells. HepG2 cells were transfected with ERa expression 
vector for 24 hours. The cells were pretreated with l|iM ICI 182 780 for 3 hours 
before adding 10|j,M genistein for further 48 hours. The cells were incubated with 
[1 p-^H(N)] -androst-4-ene-3,17-dione for 1 day. Aromatase activity was determined 
by using tritiated water release assay. Values are means 土SEM, n=3. *** P<0.0005 
vs. cells treated with 10|aM genistein only. 
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3.2.3 Differential effect of MAP kinase inhibitors 
U0126 and PD98059 are specific inhibitors of MAP kinase kinase (MEK). They both 
block phosphorylation and activation of ERK 1/2. A research group has shown that 
PD98059 would stimulate the ERE transcription, displaced radiolabeled estradiol 
from receptor and stimulate ERa- coactivator interactions (Long X. et al, 2001). 
PD98059 exhibit estrogenic activity. 
In the present study, we found out that U0126 and PD98059 exert differential effect 
on apolipoprotein Al promoter activity in ERa-transfected HepG2 cells. \\xM 
PD98059 would increase the apoAl promoter activity. lO i^M PD98059 would 
double the promoter activity, nearly to the same extent as IrjM estradiol (Figure 3.2.6 
A). However, U0126 would not show any inductive in apoAl promoter activity 
(Figure 3.2.6 B). At high concentration (10|iM), the promoter activity was even 
suppressed. As PD98059 consists of a flavonoid backbone, it might interact with ER 
to increase the apoAl promoter activity. To prevent confounding interpretation by 
the estrogenicity of PD98059, U0126 was chosen as the inhibitor of MAP kinase in 
this project. 
3.2.4 Role of MAP Kinase, PKA and PKC in genistein induced aromatase 
activity in ERa-transfected HepG2 cells 
To investigate the possible involvement of signal transduction pathway on aromatase 
activity, ERK (U0126), JNK (JNK inhibitor), p38 (SB203580), PKA (14,22-amide) 
and PKC (BI) inhibitors were used. None of the inhibitors tested, except SB203580, 
showed reduced aromatase activity in the presence of ERa (Figure 3.2.7 A). The 
genistein-induced aromatase activity could be suppressed by l|ig/|il SB203580 
(Figure 3.2.7 B). This result suggested that genistein could up-regulate aromatase 
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Figure 3.2.6 apoAl promoter activity in ERa-transfected HepG2 cells, treated with 
(A) PD98059; (B) U0126. Cells were transfected with apoAl reporter plasmid, PRL-
CMV control vector and ERa expression plasmid. Then the cells were incubated 
with different concentration of (A) PD98059 and (B) U0126 for 1 day and dual-
luciferase activity was measured. The relative luciferase activity was calculated by 
normalizing the light unit of firefly by that of renilla. Values are means 土SEM, n=3. 
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Fig 3.2.7 Effect of secondary messenger inhibitors on genistein-induced aromatase 
activity in ERa-transfected HepG2 cells. HepG2 cells were transfected with ER 
alpha expression vector for 24 hours. The cells were pretreated with different 
inhibitors for 3 hours before adding lOjiM genistein for further 48 hours. The cells 
were further incubated with [lp-^H(N)]-androst-4-ene-3,l7-dione for 1 day. 
Aromatase activity was determined by using tritiated water release assay. Values are 
means 士SEM，n=3. (* P< 0.05) 
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3.2.5 Genistein increased aromatase protein expression in ERa-transfected 
HepG2 cells 
To investigate the role of genistein on aromatase expression, western blot was carried 
out. It was found that ERa could induce aromatase expression in HepG2 cells. With 
genistein treatment, the aromatase protein expression was further elevated (Figure 
3.2.8). 
These results suggested that genistein could up-regulate aromatase protein expression 
through ER alpha in HepG2 cells. 
38 
Q j H ^ m i l i m i l l l l l l l l l l l l l l H I I I I I I I I H I I I aromatase (55kDa) 
0 0 0.1 1 10 
Genistein (uM) 
pcDNA ERa 
^ B U P m i l l l l l l l l l l l l l l l l i m P 3-actln (42kDa) 
Figure 3.2.8 Detection of aromatase protein In HepG2 cells. HepG2 cells were 
transfected with ERa expression vector and incubated with genistein for 2 days. 
Total protein was collected and the amount of aromatase was detected using Western 
Blot. The molecular weight of aromatase and p-actin was 55kDa and 42kDa 
respectively. 
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3.2.6 Genistein induced aromatase mRNA expression attributed to induction of 
exon I.l expression 
By using real time RT-PCR with probes constructed within the aromatase coding 
region, we found that the aromatase mRNA expression was elevated in a dose-
dependent manner in the presence of ERa (Figure 3.2.9). The aromatase mRNA 
expression was increased by about 3 times and 16 times with 0.1 |iM and lOjiM 
genistein treatment, respectively. Slight inductions were also observed in high 
dosages of genistein in the absence of ERa. 
The expression of aromatase is regulated by alternate splicing. To characterize the 
regulation of gene expression in HepG2, we first determined its promoter specificity 
by real time PCR using Taqman probing. In the absence and presence of ERa, the 
dominant usage was exon II. Only in the presence of ERa and lOjiM genistein, the 
mRNA expression of exon I.l was increased, while that of exon II decreased 
significantly (Figure 3.2.10). As mention in the general introduction, there are ten 
distinct tissue-specific promoters in the exons I of aromatase gene. To further 
confirm that the other promoters would not participate strongly in the regulation of 
gene expression in HepG2, we further determined its promoter specificity by RT-
PCR using various sense primers located in exon I and a common antisense primer in 
coding region of aromatase gene. From figure 3.2.11, the PCR products 
corresponding to exon I.l and II were relatively abundant in HepG2 cells, while there 
was no band detected in the other eight exons. The real time RT-PCR suggested that 
exons 1.3 and PII were the two major mRNA species present in ERa positive or 
negative HepG2 cells. After the addition of genistein in ERa-transfected HepG2 cells, 
there was a switch of the regulatory mechanism of aromatase expression from exons 
1.3 and PII to exon la. 
The aromatase activity and protein expression, induced by genistein in the presence 
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Figure 3.2.9 Effect of genistein on CYP 19 mRNA expression in HepG2 cells. HepG2 
cells were transfected with ERa expression vector and control plasmid pcDNA3.1, 
and treated with 10|j,M genistein for 48 hour. The amount of CYP 19 mRNA was 
determined by relative quantitative real time PGR. The expression of CYP 19 mRNA 
was normalized by GAPDH. Values are means 士SEM，n=3. * or # represents values 
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Figure 3.2.10 Exon I-specific real time PGR in HepG2 cells transfected with control 
plasmid (A) and ERa-transfected HepG2 cells (B). Cells were treated with lO i^M 
genistein for 48 hours. Then total RNA was extracted and reverse transcripted. Real 
time PGR was performed using Taqman probe (Table 2.2). GAPDH was amplified as 
a house keeping gene. Promoter usage levels were calculated by using method 
and expressed as percentage of total CYP19 expression. Values are means 士SEM, 
n=3. 
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Figure 3.2.11 RT-PCR amplification of alternate sites in exon I of aromatase gene 
from HepG2 cells. Cells were transiently transfected with ERa expression plasmid 
and treated with lOjiM genistein for 48 hours. Then total RNA was extracted and 
RT-PCR was carried out. The spliced exons were amplified using sense primers 
specific to exon I.l, 1.2, 1.3, 1.4，1.5，1.6，1.7 Lf, II or 2a and a common antisense 
primer located in the coding region of aromatase gene (Table 2.1). The PGR products 
were amplified for 40 cycles and separated on 1.5% agarose gel and stained with 
ethidium bromide. 
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3.2.7 Genistein induced promoter I.l transcriptional activity in ERa-transfected 
HepG2 cells 
We determined that exon I.l mRNA was elevated by genistein in ERa-transfected 
HepG2 cells. Next, we investigated whether genistein could up-regulate the 
transcriptional activity of promoter I.l. As shown in Figure 3.2.12, the result 
paralleled the mRNA data. However, genistein could not change the promoter 
activity in the absence of ERa. Such induction could be suppressed by estrogen 
antagonists ICI 182 780 (Figure 3.2.13). These results were consistent with the 
results of aromatase activity. 
To locate the sequence responsible for the induction, a series of truncate promoters 
were generated from the -700bp of promoter I.l, and inserted into the pGL3-basic 
reporter plasmid (Figure 3.2.14 A). These constructs were co-transfected into HepG2 
cells with ERa and control plasmid. Transfected cells were treated with or without 
lOjj-M genistein for two days and cell lysates were prepared for assay of luciferase 
activity assay. As shown in Figure 3.2.14 B, significant decreases in promoter 
activity in the -190 to -212, -260 to -280 and -280 to -300 deletions were observed. 
Hence, the response regions of promoter 1.1 induced by genistein could be located in 
these three sequences. 
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Figure 3.2.12 Transcriptional activity of aromatase promoter I.l in HepG2 cells. 
Cells were transfected with promoter 1.1 reporter plasmid, PRL-CMV control vector 
and ERa or pcDNA3.1 expression plasmid. Then the cells were incubated with 
10|iM genistein for 48 hours and dual-luciferase activity was measured. The relative 
luciferase activity was calculated by normalizing the light unit of firefly by that of 
renilla. Values are means 士SEM，n=3. (*P<0.05; **P<0.005) 
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Figure 3.2.13 Effect of l|xM ICI 182 780 on genistein-induced aromatase promoter 
I.l activity in ERa-transfected HepG2 cells. HepG2 cells were transfected with ER 
alpha expression vector for 24 hours. The cells were pretreated with l|iM ICI 182 
780 for 3 hours before adding 10|iM genistein for further 48 hours and dual-
luciferase activity was measured. The relative luciferase activity was calculated by 
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Figure 3.2.14 (A) A schematic diagram of the 5,-deleted mutants used in this 
experiment. (B) Transcriptional activity of a series of 5'-deleted promoter fragments 
in ERa-transfected HepG2 cells. Cells were transfected with pGL3-luciferase 
reporter constructs of promoter 1.1，ERa expression vector and PRL-CMV control 
vector for 24 hours. Then the cells were incubated with 10|iM genistein for further 
48 hours and dual-luciferase activity was measured. The results of genistein group 
were normalized by the corresponding results of DMSO group. Values are means 
土SEM, n=3. (*P<0.05; **P<0.005) 
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3.2.8 Genistein increased ERE and AP-1 reporter activity through interaction 
with ERa 
Genistein is an estrogen agonist, which can increase the aromatase promoter I.l 
activity in ERa-transfected HepG2 cells. The effect of genistein on ERE 
transactivation activity was also investigated. Figure 3.2.15 showed that ERa alone 
could not increase ERE transactivation activity. However, the activity would increase 
in the presence of ligand. Even 0.1 |xM genistein could induce ERE transactivation 
activity in ERa-transfected HepG2 cells by about 2 fold. The transactivation activity 
was further increased when the cells treated with 1 |iM and 1 OjiM genistein. 
It has been reported that ERa can interact with some transcription factors，including 
AP-1 (Cheung et al, 2005). We also investigated the effect of genistein on AP-1 in 
HepG2 cells. Even without genistein, ERa alone could induce AP-1 binding (Figure 
3.2.16). After treating with \\iM and 10|iM genistein, AP-1 binding transactivation 
activity had doubled. Hence, the result suggested that genistein induced promoter I.l 




> * * * 
I J 
0 0 0.1 |iM l^iM 10|LIM 
Genistein 
Figure 3.2.15 Effect of genistein on ERE promoter transcription activity in HepG2 
cells. Cells were transfected with ERE reporter plasmid, PRL-CMV control vector 
and ERa or pcDNA3.1 expression plasmid. Then the cells were incubated with 
10|j.M genistein for 48 hours and dual-luciferase activity was measured. The relative 
luciferase activity was calculated by normalizing the light unit of firefly by that of 
renilla. Values are means 士SEM，n=3. (** P< 0.005; *** P<0.0005) 
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Figure 3.2.16 Effect of genistein on AP-1 promoter transcription activity in HepG2 
cells. Cells were transfected with AP-1 reporter plasmid, PRL-CMV control vector 
and ERa or pcDNA3.1 expression plasmid. Then the cells were incubated with 
10|iM genistein for 48 hours and dual-luciferase activity was measured. The relative 
luciferase activity was calculated by normalizing the light unit of firefly by that of 
renilla. Values are means 士SEM, n=3. (#) represents value different from cells with 
control vector; (*) represents value different from cells with ERa and without 
genistein treatment. (*/# P< 0.05; ** P<0.005) 
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3.3 DISCUSSION 
The hepatocarcinoma cell line, HepG2, is a widely accepted model for studying 
human hepatic lipoprotein metabolism (Javitt, 1990). It has been reported that 
HepG2 cells is ER-negative (Hamish et al, 1998). Hence, they can be used for 
investigating differential pathways controlled by ER. 
Previous study has shown that ERa expression is increased in the mammary tissue of 
mice over-expressing aromatase (Kirma et al, 2001). Our data indicated that over-
expressing ERa in HepG2 cells would significantly increase the aromatase activity. 
Recently, genistein was found to increase aromatase activity in endometrial stromal 
cells via increased enzyme expression (Edmunds et al, 2005). In the present study, 
genistein exhibited estrogen-like activity and induced aromatase activity in dose and 
time-dependent manner. 0.1 }xM to lOjiM genistein could up-regulate the aromatase 
activity in the presence of ERa. Hence, ERa played a critical role in genistein-
mediated aromatase activity. The induction of aromatase activity was consistent with 
the up-regulations in aromatase protein expression, mRNA expression and promoter 
activity. 
Previously, Chen and Kinoshita (2003) have found that E2 induces aromatase 
expression in ER-positive SK-BR-3 cells through binding to the region of -300 and -
280 bp. Though promoter I.l was regarded as placenta-specific promoter, we 
identified this promoter usage was dominant in genistein-treated ERa positive 
HepG2 cells. From the promoter deletion analysis, we found that the sequences 
between -212 to -190 and -300 to -260 bp upstream of exon I.l might be responsible 
for the activity induced by genistein. These two regions might account for the 
increase of promoter I.l activity in ERa-transfected HepG2 cells. 
The classical mechanism of ER involves ligand binding to receptors in the nucleus, 
after which the receptors dimerize and bind to specific response elements (ERE) 
located in the promoter of target gene. The estrogen antagonist ICI 182 780 blocks 
the activation of AF-1 and AF-2 domain in ERa (Lu et al, 2002). ICI 182 780 
completely abolished the genistein-induced aromatase activity and promoter activity, 
indicating that ERa activation regulated the gene transcription. Though the addition 
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of genistein could increase the ERE transactivation activity, there was no ERE 
consensus sequence found within promoter LI. Previous findings suggested that ERa 
can regulate the gene expression without binding to the DNA directly. Instead, it can 
interact with other transcription factors, including AP-1, Spl, NF-KB. The 
transcription factors would bind to their corresponding response element to trigger 
the gene transcription, instead of binding to ERE (Paech et al, 1997; Porter et al, 
1997; Ray et al, 1997; Webb et al, 1999; Bjornstrom & Sjoberg, 2005). Our lab 
previously has demonstrated that genistein would not affect Spl mRNA expression 
in ERa-transfected HepG2 cells (Yuen, 2005). In the present study, the results 
suggested that genistein would up-regulate the AP-1 site in a dose dependent manner. 
Within the regions of promoter 1.1，several AP-1 sites are detected, including -498 
and -935 in promoter II and 1.3 (Zhou et al, 1996). Two putative AP-1 sites have 
been found between -70 bp and the start site of exon I.l (Chen and Kinoshita, 2003). 
-212 to -190 region of exon I.l was important in the genistein-mediated aromatase 
activity. It may due to an AP-1 binding site (TGTGGGTCATA) located in -211 to-
201 of this region. 
Emerging evidence indicated the importance of signaling pathway in the actions of 
ER. The extracellular-regulated kinase (ERK) and p38 MAPK pathways are shown 
to initiate ER phosphorylation at key positions (McClelland et al, 2001; Knowiden 
et al, 2003). Other research groups have shown that MAPK mediated cross talk 
occurs between growth factor and estrogen receptor (Bunone et al, 1996; Font de 
Mora and Brown, 2000). Estrogen can activate the MAPK pathway in mammalian 
cells by interacting with membrane or cytosol ER (Migliaccio et al, 1996; Walters et 
al, 1997; Manolagas & Kousteni，2001; Lu et al, 2004). On the other hand, 
genistein can inhibit protein tyrosine kinase (Akiyama et al., 1987 ； Barnes et al., 
2000). It inhibits the nongenomic effect of estradiol on protein kinase C (PKC) 
activity in chondrocytes isolated from female rats (Sylvia et al, 2000). However, 
ERK, JNK, PKA and PKC pathways were not involved in the genistein-induced 
aromatase activity in the present study. Only inhibition of p38 MAPK pathway could 
partly abolish the induction. Lee and Bai (2002) have suggested that the kinase 
responsible for phosphorylating ER at Thupn may be a member of the p38 family. 
Genistein rapidly and significantly activates p38 in immortalized human mammary 
epithelial cells (Frey and Singletary, 2003). The possibility that genistein 
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phosphorylates ER through p38 and promotes aromatase activity needs further 
investigation. 
In the present study, we demonstrated that genistein could significantly increase the 
aromatase activity in the ERa-transfected HepG2 cells. Genistein could increase the 
promoter activity, mRNA and protein expression of aromatase in ERa-transfected 
HepG2 cells. -300 to -260 and -212 to -190 regions in promoter I.l were critical in 
the up-regulation of aromatase activity. Such induction was possibly mediated 
through AP-1 activation pathway. As estrogen can trigger a wide-range of gene 
transcriptions in liver, this study provided a new insight for the gene-regulatory 




C H A P T E R 4 
EFFECT OF 2,3,7,8-TETRACHLORODIBENZO-IMIL4-
T C D D ( T C D D ) ON AROMATASE IN M C F - 7 CELLS 
4.1 INTRODUCTION 
4.1.1 Breast Cancer 
In Hong Kong, breast cancer is the most common cancer affecting female. It is 
ranked the third major cause of cancer death (Hong Kong Cancer Registry, 2004). 
There are several risk factors which contribute to the etiology of breast cancer, 
including age, race, genetic, physical activity and diet (American Cancer Society). 
Nearly 60% of pre-menopausal and 75% of postmenopausal breast cancer patients 
have hormone-dependent tumors. Lifetime exposure to estrogens is a major risk 
factor for both breast and endometrial cancer in women (Hulka, 1997; Hulka et al, 
1994). The positive correlation between estrogen exposure and breast cancer has 
been demonstrated in cell and animal models (Colditz, 1999; Yoshidome et al., 
2000). 
4.1.2 TCDD 
Environmental pollution is getting increasingly serious nowadays. Poly cyclic 
aromatic hydrocarbons (PAHs) belong to a class of environmental contaminants that 
could be found in diesel exhaust, tobacco smoke and over-heated cooking oil (lARC, 
1983; EPC, 1990). PAHs have been widely studied on the effect of DNA adduct 
formation and carcinogensis. The compound 2,3，7,8-tetrachlorodibenzo-/7ara-TCDD 
(TCDD) is considered to be the most toxic member of a class of planar, halogenated 
aromatic hydrocarbons (Bimbaum, 1994; Birnbaum, 1995). Its chemical structure is 
contains two aromatic rings connected through a pair of oxygen atoms. Four chlorine 
atoms, two on each aromatic ring, are attached at positions 2, 3, 7 and 8. 
TCDD is a widespread environmental contaminant produced by different chemical 
reactions, waste incineration and incidental formation in pesticides producing plants 
(Zook et al, 2003; Tuppurainen et al, 2003). As TCDD is extremely stable and 
highly lipophilic, it can accumulate in the food chain (Birnbaum, 1994). The half life 
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of TCDD in human is about 7-9 years (Pirkle et al., 1989). Animal products in our 
diet account for 90% of our TCDD exposure (Baars et al., 2004). The persistence and 
ubiquity in the environment make it difficult to determine the pollutant's impact on 
human health. In 1997, the International Agency for Research on Cancer (lARC) 
classified TCDD as a Group I carcinogen, which can increase the mortality for all 
cancers. It is shown that TCDD is a multi-site carcinogen in both animal and human 
studies (lARC, 1997). Moreover, TCDD affects the male and female reproductive 
system and on sexual and learning behavior in rats and monkeys (Peterson et al, 
1993; Kociba et al.’ 1976; Mably et al, 1992a,b). 
4.1.3 CYP enzymes 
There are at least 25 distinct classes of CYP enzymes identified (Guengerich, 1994). 
Based on the similarities in the amino acid sequences, CYP enzymes are divided into 
families and subfamilies. Generally, CYP 1 to 4 families are responsible for the 
metabolism of xenobiotics. CYP 5 to 27 families are involved in endogenous 
substrates synthesis and metabolism (Nelson et al, 1993). Most researches of TCDD 
are concentrated on the effect on certain aryl hydrocarbon receptor (AhR) activated 
CYP enzyme, including CYPlAl, CYP1A2 and CYPIBI, which catalyze the 
activation of a wide range of chemical carcinogens (Chen et al, 2004; Bofinger et al’ 
2001; Safe, 1994). Upon TCDD binding, HSP90 will be released from AhR. The 
activated AhR will then translocate to the nucleus. AhR forms heterodimer complex 
with the structurally related AhR nuclear translocator protein (ARNT). The activated 
complex binds to specific gene regulatory sequences, known as xenobiotic response 
element (XRE). This binding activates transcription of several genes, especially 
CYPs which are involved in xenobiotic compound metabolism (Schrenk, 1998; 
Whitlock, 1990; Swanson and Bradfield, 1993; Whitlock, 1993; Hankinson, 1995; 
Whitlock et al., 1997). However, the effect of TCDD on aromatase activity is 
seldomly investigated in human breast cancer cells. 
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4.1.4 TCDD and breast cancer 
TCDD is involved in the modulation of estrogen in many paradigms. In rats, 17 p-
estradiol-induced uterine responses, uterine weight, peroxidase activity, estrogen 
receptor, and progesterone receptor were decreased after the treatment of TCDD 
(Astroff and Safe, 1990; Romkes and Safe, 1988). Several studies have shown that 
TCDD inhibits diverse E2-induced responses (Safe, 1995). TCDD acts as an 
antiestrogen by suppressing estrogen-stimulated growth of human MCF-7 breast 
cancer xenografts (Gierthy et al, 1993). It also reduces the level of estrogen receptor 
in MCF-7 (Harris et al’ 1990). However, other group has indicated that TCDD does 
not affect the total estrogen receptor levels (Gierthy et al., 1987). 
Environmental toxicants are thought to play a role in several estrogen-dependent 
diseases including breast cancer. In 1976，an industrial explosion in Seveso, Italy, 
resulted in high TCDD exposure to the residential populations (Mocarelli and 
Pocchiari, 1988). In the Seveso Women's Health study, individual's serum TCDD 
level was associated with breast cancer risk, contrasting to its antiestrogenic effect in 
breast cancer cells (Warner et al, 2002). The anti-estrogenic activity of TCDD could 
not account for the increased breast cancer risk. The possibility that TCDD possesses 
estrogenic effect should be considered. Due to the functional role of aromatase to 
convert androgen into estrogen, it may play a role in the TCDD-induced breast 
cancer. 
4.1.5 Aim of study 
The aim of the present study was to examine whether TCDD could increase 
aromatase activity in human breast cells and might therefore increase the risk of 
breast cancer. In our experiment design, we employed different human breast cancer 
cell models for this purpose. 
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4 .2 RESULT 
4.2.1 Effect of TCDD on aromatase activity in different cell lines 
In the present study, six breast cancer cell lines (MCF-7, T47D, MCF-lOA, MDA-
MB-231and SK-BR-3) and one liver cancer cell line (HepG2) were screened for the 
aromatase induction by lOrjM TCDD. As shown in figure 4.2.1, lOrjM TCDD could 
not induce aromatase activity in T47D, MCF-lOA and MDA-MB-231cell lines. 
Aromatase activity of untreated SK-BR-3 cells was 10.450 士 0.2828 cpm/ jig protein/ 
hour, and the activity was elevated to 2204.603 士 527.3202 cpm/ |ig protein/ hour 
after transfected with ERa (Figure 4.2.2). The activity of ERa-transfected cells 
elevated significantly, nearly 220 times higher than that in the untreated cells. 
Similar to HepG2 cells, ERa transfection increased aromatase activity in SK-BR-3 
cells. However, 10r|M TCDD could not further induce the aromatase activity in the 
presence or absence of ERa (Figure 4.2.3). 
In the absence of ERa, lOrjM TCDD would not increase the aromatase activity in 
HepG2 cells. In the presence of ERa , lOriM TCDD elevated the activity by 2-fold 
and such induction could be suppressed by ICI 182 780 (Figure 4.2.4). Hence, TCDD 
could induce aromatase activity via ERa in HepG2 cells. 
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Figure 4.2.1 Aromatase activity in (A) T47D，(B)MCFIOA and (C) MDA-MB-231. 
Cells were treated for 48 hour lOrjM TCDD and were then further incubated with 
[1 p-^H(N)]-androst-4-ene-3,17-dione for 1 day. Aromatase activity was determined 












Figure 4.2.2 Aromatase activity in SK-BR-3 cells. SK-BR-3 cells were transfected 
with ER alpha expression vector and control plasmid pcDNA3.1. The cells were 
further incubated with 25r|M [ 1 p-^H(N)]-androst-4-ene-3,17-dione for 3 hours. 
Aromatase activity was determined by using tritiated water release assay. Values are 
means 士SEM，n=3. *P<0.05 vs. control plasmid cells. 
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Figure 4.2.3 Aromatase activity in SK-BR-3 cells. SK-BR-3 cells were transfected 
with ER alpha expression vector and control plasmid pcDNA3.1, and treated with 
lOrjM TCDD for 48 hour. The cells were further incubated with 25r|M [ip-^H(N)]-
androst-4-ene-3,17-dione for 3 hours. Aromatase activity was determined by using 
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Figure 4.2.4 Effect of lOriM TCDD on aromatase activity in HepG2 cells. HepG2 
cells were transfected with ERa expression vector for 24 hours. The cells were 
pretreated with \\iM ICI 182 780 for 3 hours before adding 10r|M TCDD for further 
48 hours. The cells were further incubated with [ 1 P-^H(N)]-androst-4-ene-3,17-dione 
for 1 day. Aromatase activity was determined by using tritiated water release assay. 
Values are means 士SEM, n=3. * P<0.05 vs. cells transfected with ERa only; • 
P<0.005 vs. cells treated with TCDD in the presence of ERa. 
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4.2.2 TCDD increased aromatase activity in MCF-7celIs 
The regulation of aromatase activity in MCF-7 cells was determined by titrated water 
release assay. The cells were incubated with various concentration of TCDD. 
Aromatase activity was assessed using the release of [^H]H20 into media. The time 
course of the effect of lOrjM TCDD on the aromatase activity in MCF-7 cells was 
investigated over a 48 hour period (Figure 4.2.5). TCDD could not induce aromatase 
activity in both 6 hours and 24 hours. However, incubating the cells with TCDD for 
48 hours increased the aromatase activity nearly by two times. Hence, the cells 
would be incubated in TCDD for 48 hours in the following experimental design. 
The dose-dependent effect was studied by culturing the cells with various 
concentration of TCDD for 48 hours. TCDD could induce aromatase activity in a 
f 
dose-dependent manner. TCDD increased the activity slightly at 0.1r|M while about : 
2-fold increase was observed at lOrjM (Figure 4.2.6). Such induction could be \ 
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Figure 4.2.5 Time course of TCDD stimulation of the aromatase activity in cultured 
MCF-7 cells. MCF-7 cells were treated for various time periods with TCDD at 10r|M. 
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Figure 4.2.6 Dose-response of TCDD stimulation of the aromatase activity in 
cultured MCF-7. MCF-7 cells were treated for 48 hour with different concentration 
of TCDD and were then further incubated with [ 1 p-^H(N)] -androst-4-ene-3,17-dione 
for 1 day. Aromatase activity was determined by using tritiated water release assay. 
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Figure 4.2.7 Effect of l|iM ICI 182 780 on TCDD-induced aromatase activity in 
MCF-7 cells. The cells were pretreated with l^iM ICI 182 780 for 3 hours before 
adding 10r|M TCDD for further 48 hours. The cells were further incubated with [Ip-
^H(N)]-androst-4-ene-3,17-dione for 1 day. Aromatase activity was determined by 
using tritiated water release assay. Values are means 士SEM, n=3. *** P<0.005 vs. 
cells treated with 10r|M TCDD. 
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4.2.3 Effect of TCDD on human CYP19 recombinant Supersomes® and MCF-7 
aro cells 
The effect of TCDD on aromatase activity was also determined using CYP 19 
recombinant protein (Supersomes®). Incubation of 2 pmol Supersomes® with 25nM 
of the radioactive substrate for 15 minutes resulted in an activity of 14607.51 士 
613.65 cpm/ pmol. However, addition of TCDD did not show any effect on the 
aromatase activity (Figure 4.2.8). 
We have also tested the effect of TCDD on MCF-7 cells stably transfected with 
aromatase. The aromatase activity in MCF-7aro cells was about 40 times higher than 
that assayed in the control MCF-7vec cells (Wang, 2005). Upon TCDD treatment, 
there was neither stimulatory nor inhibitory effect on aromatase activity. The 
aromatase activity remained at around 3, 300 cpm/|j.g protein/ hour (Figure 4.2.9). 
Hence, TCDD did not directly stimulate aromatase enzyme complex. Other possible 
factors and mechanisms should be considered. 
4.2.4 TCDD increase aromatase protein expression in MCF-7 cells 
To investigate the role of TCDD on aromatase expression, western blot was carried 
out. It was found that TCDD could dose-dependently induce aromatase expression in 
MCF-7 cells (Figure 4.2.10). These results suggested that TCDD could up-regulate 
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Figure 4.2.8 aromatase enzyme assay performed on hCYP19 Supersomes®. 
Incubation of 2pmol hCYP19 Supersomes® with 25 r|M of the substrate [ip-^H(N)]-
androst-4-ene-3,17-dione and different concentration of TCDD for 15mins. 
Aromatase activity was determined by using tritiated water release assay. Values are 
means 士SEM, n=3. 
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Figure 4.2.9 Aromatase activity in MCF-7 aro cells. Cells were treated for 48 hour f 
I' 
lOrjM TCDD and were then further incubated with [ 1 P-^H(N)] -androst-4-ene-3,17-
dione for 1 day. Aromatase activity was determined by using tritiated water release 
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Figure 4.2.10 Effect of TCDD on aromatase protein expression in MCF-7 cells. 
MCF-7 cells were incubated with TCDD for 2 days. Total protein was collected and 
the amount of aromatase was detected using Western Blot. The molecular weight of 
aromatase and p-actin were 55kDa and 42kDa respectively. 
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4.2.5 Effect of TCDD in aromatase mRNA expression in MCF-7 cells 
By using Taqman probing within the aromatase coding region, there was no 
significantly change in the aromatase mRNA expression after treatment of 0.1 and 
lr|M TCDD in MCF-7 cells. However, the mRNA expression was increased by 
roughly 300% at IOTIM TCDD (Figure 4.2.11). 
By performing real time PCR, we noticed that the dominant promoter usage in MCF-
7 were exons II and 1.3, contributing for 90% and 6% of total transcriptional activity 
respectively. Exons I.l contributed for only 4%. After the addition of TCDD, the 
promoter usage did not show any significant changes (Figure 4.2.12). 
！ 
4.2.6 Effect of TCDD in CYP19 promoter and AP-1 promoter activity in MCF-7 | 
cells 
丨' 
The proximal promoter II located in the immediate upstream region of the translation 
start site, while promoter 1.3 is about 200bp proximal to promoter II (Sebastian and 
Bulun, 2001). They share common regulatory elements (Mahendroo et al, 1993). As ‘ 
I 
the dominant promoters in MCF-7 are I.l, 1.3 and II，we further investigated the ； 
effect of TCDD on promoters I.l and I.3/II. As shown in figure 4.2.13，treatment , 
丨  
j； 
with lOriM TCDD for 2 days would not change the promoter activities. ：;, 
j . 
I' 
AP-1 is another response element that ER could interact with (Cheung et. al, 2005). | 
i: 
Previous finding has shown that promoter I.3/II bears the consensus sequences of ！ 
AP-1 at -498 and -935 (Zhou D.，et al., 1996). Effect of TCDD on AP-1 interaction 
was investigated in the present study. Figure 4.2.14 showed that various 
concentrations of TCDD could not change the reporter activity of AP-1 in MCF-7 
cells. This result suggested that TCDD-induced aromatase activity was not associated 
with interaction of AP-1. Hence, the induction of aromatase activity and protein 
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Figure 4.2.11 Effect of TCDD on CYP 19 mRNA expression in MCF-7 cells. Cells | 
were treated with TCDD for 48 hours. The amount of CYP 19 mRNA was 
i 
determined by relative quantitative real time PGR. The expression of CYP 19 mRNA ‘ 
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Figure 4.2.12 Exon I-specific real time PGR in MCF-7 cells. Cells were treated with 
lOrjM TCDD for 48 hours. Then total RNA was extracted and reverse transcribed. 
Real time PGR was performed using Taqman probe (Table 2.2). GAPDH was 
amplified as a house keeping gene. Promoter usage levels were calculated by using 2" 
••CT method and expressed as percentage of total CYP 19 expression. Values are 
means 士SEM, n=3. 
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Figure 4.2.13 Effect of TCDD on (A) CYP19 promoter I.3/II and (B) CYP19 
promoter I.l activity in MCF-7 cells. Cells were transfect with (A) promoter I.3/II 
and (B) promoter I.l reporter plasmid, control vector PRL-CMV and treated with 
10r|M TCDD for 48 hours. Then cells were lysed and dual luciferase assay was 
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Figure 4.2.14 Effect of TCDD AP-1 promoter activity in MCF-7 cells. Cells were 
transfect with AP-1 reporter plasmid, control vector PRL-CMV and treated with 
10r|M TCDD for 48 hours. Then cells were lysed and dual luciferase assay was 
performed. Values are means 土SEM，n=3. 
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4.2.7 Effect of TCDD in CYP19 mRNA Half-life 
To investigate the mechanism of post-transcriptional regulation, the half-life of the 
CYP 19 mRNA was determined. The cells were treated with TCDD for 2 days before 
addition of actinomycin D. Actinomycin D intercalates into DNA to immobilize the 
complex and interfere the elongation of growing RNA chains. Thus, the progression 
of RNA polymerases, especially for the RNA polymerases I，would be inhibited 
(Sobell 1985; Perry and Kelley, 1970). The data presented in Figure 4.2.15 show that 
TCDD double the half-life of the CYP 19 mRNA by approximately 5 hours to 10 
hours. The addition of ERK inhibitor, U0126, could successfully abolish the TCDD-
induced CYP 19 mRNA expression (Figure 4.2.16). These data suggested that the 
increase in CYP 19 mRNA was caused by a post-transcriptional effect of TCDD on 
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Figure 4.2.15 Effect of TCDD on CYP 19 mRNA half-life. MCF-7 cells were seeded 
in 6-well plates. After 48-hour treatment with lOrjM TCDD, transcription was 
stopped by 4|iM actinomycin D. Total RNA was isolated and analyzed by real time 
PGR as described in Figure 4.2.11. Values are presented as percentage of RNA at 0 
hour. Values are means 士SEM，n=3. 
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Figure 4.2.16 Effect of U0126 on TCDD-induced CYP 19 mRNA half-life. MCF-7 
cells were seeded in 6-well plates. The cells were pretreated with 10|iM U0126 for 3 
hours before adding lOrjM TCDD for further 48 hours. The transcription was 
stopped by 4|iM actinomycin D. Total RNA was isolated and analyzed by real time 
PGR as described in Figure 4.2.11. Values are presented as percentage of RNA at 0 
hour. Values are means 士SEM, n=3. 
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4.2.8 Role of MAP Kinase, PKA and PKC in genistein induced aromatase 
activity in MCF-7 Cells 
To investigate the role of TCDD signaling pathway on aromatase activity, MAP 
kinase, PKA and PKC pathways were studied. SB203580, a p38 pathway inhibitor, 
did not suppress the induction of aromatase by TCDD (Figure 4.2.17 B). In contrast, 
JNK inhibitor II and U0126 would suppress the induction back to the original level 
(Figure 4.2.17 A). Similar trend can be observed in figure 4.2.18, the increased 
aromatase activity returned to the original level after the pre-treatment of PKA or 
PKC inhibitor. The induction of aromatase activity by TCDD could be mediated, at 
least partly, via ERK, JNK, PKA and PKC pathways. 
4.2.9 TCDD induced ERKl/2 Activation 
To further study the role of TCDD in ERK signaling pathway, ERK 1/2 
phosphorylation was studied. It was found that TCDD could not induce the inactive 
form of ERK, but increase the phosphorylation of ERK 1/2 in a dose dependent 
manner in MCF-7 cells (Figure 4.2.19). This suggested that TCDD might up-regulate 
aromatase expression through of ERK 1/2 pathway. 
4.2.10 Induction of aromatase activity in MCF-7ERK cells 
To investigate the relationship between ERK and aromatase, ERK over-expressing 
MCF-7 cells (MCF-7ERK) and the vector control cells (MCF-7vec) had been studied. 
When MCF-7ERK cells were incubated with [ 1 p-^H(N)]-androst-4-ene-3,17-dione for 
1 day, the aromatase activity was around 1.5 times higher than the control vector 
cells (Figure 4.2.20). The aromatase protein expression (Figure 4.2.21) and mRNA 
expression (Figure 4.2.22) in MCF-7ERK cells were higher than those in the MCF-7vec 
cells. The mRNA expression in MCF-7ERK cells was nearly 5 times higher than the 
control. However, the aromatase promoter activities in MCF-7ERK and MCF-7VEC 
cells are nearly the same (Figure 4.2.23). The half life of CYP 19 mRNA in MCF-
7ERK cells was slightly higher than the control cells (Figure 4.2.24). The induction 
mechanism would be through post-transcriptional control. Hence, over-expressing 
ERK in MCF-7 cells would induce the expression of aromatase. This implicated that 
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Figure 4.2.17 Inhibition of TCDD-mediated induction of aromatase activity in MCF-
7 cells by (A) U0126 and JNK inhibitor II; (B) 1 昭/|il SB203580. Pre-treatment the 
cells with (A) l|iM U0126 and l^M JNK inhibitor II; (B) 1 昭尔 1 SB203580 for 3 
hours before adding 10r|M TCDD for further 48 hours. The cells were further 
incubated with [ 1 P-^H(N)]-androst-4-ene-3,17-dione for 1 day. Aromatase activity 
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Figure 4.2.18 Inhibition of TCDD-mediated induction of aromatase activity in MCF-
7 cells by l|iM bisindolylmaleimide I (BI) and 1 |ig/|il myristoylated 14-22 amide 
(amide). Pre-treatment the cells with l|iM BI and 1 lag/p-l amide for 3 hours before 
adding lOriM TCDD for further 48 hours. The cells were further incubated with [ip-
^H(N)]-androst-4-ene-3,l7-dione for 1 day. Aromatase activity was determined by 
using tritiated water release assay. Values are means 士SEM，n=3. **P<0.005; 
*P<0.05 vs TCDD treated MCF7 cells. 
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Figure 4.2.19 Effect of TCDD on phospho-ERKl/2 expression. MCF-7 cells were 
treated with various concentration of TCDD for 48 hours. Total protein was collected 
and the amount of phospho-ERKl/2 was detected using Western Blot. The molecular 
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Figure 4.2.20 Aromatase activity in MCF-7vec and MCF-7ERK cells. Cells were 
maintained in RPMI medium and switch to charcoal treated RPMI medium one day 
before doing the assay. In the next day, the cells would incubate in serum-free 
medium with the addition of [ 1 p-^H(N)]-androst-4-ene-3,17-dione for 1 day. The 
activity was determined by tritiated water release assay. Values are the means 士SEM， 
n=3. (* P<0.05) 
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Figure 4.2.21 Aromatase protein expression in MCF-7vec and MCF-7ERK cells. Cells 
were maintained in RPMI medium and switch to charcoal treated RPMI medium one 
day before lysate. Total protein was collected and the amount of aromatase was 
detected using Western Blot. The molecular weights of aromatase and p-actin are 
55kDa and 42kDa respectively. 
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Figure 4.2.22 CYP19 mRNA expression in MCF-7ERK cells. mRNA were extracted 
in MCF-7vec and MCF-7ERK cells. The amount of CYP19 mRNA was determined by 
relative quantitative real time PCR. The expression of CYP19 mRNA was 
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Figure 4.2.23 CYP19 promoter activities in M C F - 7 v e c and MCF-7ERK cells. Cells 
were transfect with promoter I.3/II, promoter I.l reporter plasmid and control vector 
PRL-CMV. After 24 hours, the cells were lysed and dual luciferase assay was 
performed. Values are means 士SEM，n=3. 
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Figure 4 .2 .24 The C Y P 1 9 mRNA half-life in MCF-7ERK cells. MCF-7vec and M C F -
7ERK cells were seeded in 6-well plates for 24 hours. The transcription was stopped 
by actinomycin D. Total RNA was isolated and analyzed by real time PGR as 
described in Figure 4.2.11. Values are presented as percentage of RNA at 0 hour. 
Values are means 士SEM，n=3. 
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4 .3 DISCUSSION 
Results of the present study showed that TCDD could increase aromatase activity in 
MCF-7, ER-positive HepG2 cells, but not MCF-lOA，T47D and MB-MDA-231 cells. 
It was indicated that over-expression of ERa in SK-BR-3 cells would increase the 
aromatase expression. Addition of estrogen could induce the aromatase activity in 
ERa-transfected SK-BR-3 cells (Kinoshita and Chen, 2003; Wang, 2005). Though 
we also found that over-expressing ERa in SK-BR-3 cells elevated the aromatase 
activity dramatically, addition of TCDD could not show further induction of 
aromatase activity both in the absence and presence of ERa. Surprisingly, addition of 
TCDD in the presence of ERa could induce aromatase activity in the human liver 
cancer cell line HepG2. Such induction was suppressed by estrogen antagonist, ICI 
182 780. 
Most researches, both in vitro and in vivo studies, showed the anti-estrogenicity of 
TCDD (Safe et al, 1991; Gallo et al, 1986; Gierthy et al, 1987). It has been 
documented that TCDD decreases aromatase activity in human choriocarcinoman 
cells (Drenth et al, 1998). However, the estrogenic effect of TCDD has seldomly 
been reported. Recently, an environmental toxicants 2,2-bis(p-chlorophenyl)ethylene 
(p,p'-DDE) and TCDD have been shown to increase aromatase activity in cultures of 
endometrial stromal cells (Holloway et al., 2005; Stys et al, 2005). Results in this 
study showed that TCDD could also induce aromatase activity in MCF-7 cells. The 
cells treated with 10r|M TCDD for two days had double or triple aromatase activity 
than the control. Induction of aromatase expression by TCDD occurred within the 
same concentration range. Additional experiments performed with human CYP 19 
Supersomes® indicated that this induction was unlikely a direct stimulatory effect of 
TCDD on the aromatase enzyme complex. This result is similar to the one performed 
in microsomal fractions of human placental tissue (Drenth et al, 1998). 
TCDD has previously been found to increase aromatase mRNA expression in 
endometrial stromal cells (Stys et al” 2005). In this study, we observed comparable 
results in MCF-7 cells. It is demonstrated that promoters II and 1.3 are the major 
promoters driving aromatase expression in MCF-7 cells (Mu et al, 2000), bearing 
consensus sequences of AP-1 at -498 and -935 (Zhou D et al, 1996). In our study, 
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MCF-7 was shown to use promoter II, 1.3 and I.l. However, the exon 1.1，II and 1.3 
expressions surprisingly were not up-regulated. There was no induction observed in 
promoters I.l; L3/II activities nor AP-1 transactivation activity after the treatment of 
TCDD. Hence, it appeared that TCDD mediated aromatase activity through an 
atypical transcriptional control in MCF-7 cells. 
Post transcriptional regulations, which encompass nuclear RNA processing, 
exporting RNA from the nucleus and mRNA degradation, have become increasingly 
important in the regulation of cytoplasmic mRNA levels. 12-0-
tetradecanoylphorbol-13-acetate (TPA) decreases ER levels through a post-
transcriptional destabilization of the ER mRNA (Saceda et al, 1991). Estradiol 
decreases ER expression in MCF-7 cells predominantly by a post-transcriptional 
mechanism (Saceda et al, 1998). The data in present study suggested that TCDD 
could increase the half-life of CYP19 mRNA. The mechanism of CYP19 mRNA 
decay needs further investigation. 
MCF-7 is a ER-positive cell line derived from a metastatic adenocarcinoma of 
human breast, which is widely used for studying estrogen-dependent mechanism. 
Addition of estrogen antagonist ICI 182 780 could abolish the induction of aromatase 
by TCDD. This suggested ERa might play an important role in the induction 
mechanism. However, TCDD could not show induce the activity in T47D, which is 
also a ERa-positive breast cancer cell line. Hence, ERa alone could not give a whole 
picture of the story. It is widely accepted that the major effect of TCDD is mediated 
through the activation of aryl hydrocarbon receptor (AhR) (Nebert et al, 1993; Okey 
et al, 1994; Chen et al, 2004). Wild-type MCF-7 and Hepa/lclc7 cells are Ah-
responsive. TCDD decreases ER levels in these cells, but not in two mutant Ah non-
responsive Hepa lclc7 cell lines (Harris et al, 1990; Zacharewski et al, 1991). Baba 
et al (2005) has demonstrated that AhR is crucial in female reproduction by 
regulating the expression of ovarian aromatase. AhR cooperates with an orphan 
nuclear receptor, Ad4BP/SF-l, to activate aromatase gene transcription in ovarian 
granulosa cells. Functional cross talk between AhR and ER has been reported 
(Wormke et al, 2000; Ohtake et al, 2003). The ligand-bound AhR activates the 
ligand-less ER to interact with ERE in target gene promoter (Ohtake et al, 2003). By 
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studying the role of AhR in TCDD-induced aromatase might give us some clues in 
the complex mechanism in the future. 
ERa is phosphorylated and activated by several signaling kinases, including ERK 1/2, 
p38 and PKA (Kato et al, 1995; Lee and Bai, 2002; Cho and Katzenellenbogen, 
1993; Chen D. et al, 1999; Loven et al, 2004). Estrogen can cause rapid activation 
of MAPK pathway in mammalian cells through ligand-binding with ER (Lu et al, 
2004). Our lab also reported that estrogen could induce the phosphorylation of ERK 
1/2 in ERa-transfected SK-BR 3 cells (Wang, 2005). Hence, the importance of 
signaling kinase should not be ignored. Previous studies on interaction of TCDD 
with aromatase have not investigated the involvement of signaling pathways (Drenth 
et al, 1998; Stys et al, 2005). In this project, we investigated the MAP kinase and 
protein kinase pathways by adding the corresponding inhibitors. The results showed 
that ERK, JNK, PKA and PKC could take part in the regulation process. 
Brodie et al. (2005) have implanted aromatase over-expressing MCF-7 cells into 
ovariectomized and nude mice. They found that tumor cells adapt to estrogen 
deprivation during letrozole treatment by activation of p-Raf, p-MEKl/2 and p-
MAPK. Previously, our lab successfully established an ERK over-expressing MCF-
7 cell line. The aromatase activity, protein, mRNA expression and mRNA stability in 
MCF-7ERK cells were higher than that of the control cells. Hence, ERK is a 
regulatory factor of aromatase in MCF-7 cells. TCDD could increase the ERK 
protein expression in MCF-7 in a dose-dependent manner. Addition of ERK 
inhibitors would abolish the TCDD-induced aromatase activity in MCF-7 cells. 
Hence, the observed modulation of the aromatase activity could be ERK-mediated. 
To summarize, TCDD could increase the aromatase activity in MCF-7 cells. Though 
TCDD could not up-regulate CYP 19 transcriptional activity, it increased the mRNA 
stability by way of ERK activation. Hence, the aromatase mRNA, protein expression 
and enzyme activities were increased. Further investigation should be carried out in 
order to elucidate the mechanism. 
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C H A P T E R 5 SUMMARY 
Aromatase catalyzes the hydroxylation reactions converting androstenedione and 
testosterone into estrone and estradiol respectively (Simpson et al, 1994). It is 
generally accepted that estrogen is important in the prevention of the cardiovascular 
disease. 17p-estradiol (E2) has been shown to up-regulate apoAl and LDLR in 
HepG2 cells (Yuen, 2005; Lamon-Fava et al, 1999). In the present study, we 
demonstrated that genistein could significantly increase the aromatase activity in the 
ERa-transfected HepG2 cells. AP-1 and p38 pathway might be involved in the 
induced aromatase activity in ERa-transfected HepG2 cells (Figure 5.1.A). As 
estrogen can trigger a wide-range of gene transcriptions in liver, including apoAl 
and LDLR, this study provided a new insight for the gene-regulatory mechanism of 
genistein. 
On the other hand, estrogen exposure has been proven to be a negative component in 
breast cancers. In the present study, effect of TCDD on aromatase was evaluated. 
Among all the breast cancer cells tested, TCDD could only increase the aromatase 
activity in MCF-7 cells possibly through a post-transcriptional regulation (Figure 
5.LB). The mRNA degradation results showed that TCDD could increase the 
aromatase mRNA stability. In studying the ERK over-expressing MCF-7 cells, there 
was a close relationship between ERK and aromatase activity. The observed 
modulation of the aromatase activity by TCDD could be ERK-mediated. 
To conclude, genistein and TCDD could mediate the aromatase activities in HepG2 
and MCF-7 cells respectively. The results obtained provide a better insight of the 
genistein and TCDD induced aromatase mechanisms. The findings could better our 
understanding of the estrogenic effect of genistein and the pathway involved in 
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